206 related articles for article (PubMed ID: 31749075)
1. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
Shebley M; Polepally AR; Nader A; Ng JW; Winzenborg I; Klein CE; Noertersheuser P; Gibbs MA; Mostafa NM
Clin Pharmacokinet; 2020 Mar; 59(3):297-309. PubMed ID: 31749075
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
[TBL] [Abstract][Full Text] [Related]
3. Elagolix: First Global Approval.
Lamb YN
Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
[TBL] [Abstract][Full Text] [Related]
4. Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain.
Abbas Suleiman A; Nader A; Winzenborg I; Beck D; Polepally AR; Ng J; Noertersheuser P; Mostafa NM
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):639-648. PubMed ID: 32945631
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.
Winzenborg I; Nader A; Polepally AR; Liu M; Degner J; Klein CE; Mostafa NM; Noertersheuser P; Ng J
Clin Pharmacokinet; 2018 Oct; 57(10):1295-1306. PubMed ID: 29476499
[TBL] [Abstract][Full Text] [Related]
6. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.
Carr B; Dmowski WP; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
Reprod Sci; 2014 Nov; 21(11):1341-51. PubMed ID: 25249568
[TBL] [Abstract][Full Text] [Related]
7. Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis.
Stodtmann S; Nader A; Polepally AR; Suleiman AA; Winzenborg I; Noertersheuser P; Ng J; Mostafa NM; Shebley M
Clin Transl Sci; 2021 Jul; 14(4):1611-1619. PubMed ID: 33963686
[TBL] [Abstract][Full Text] [Related]
8. Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment.
Ng J; Duan WR; Marbury T; Schmidt JM; Klein CE
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1053-1061. PubMed ID: 30570832
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
[TBL] [Abstract][Full Text] [Related]
10. Elagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain.
Med Lett Drugs Ther; 2018 Sep; 60(1556):158-160. PubMed ID: 30383729
[No Abstract] [Full Text] [Related]
11. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
[TBL] [Abstract][Full Text] [Related]
12. A Clinician's Guide to the Treatment of Endometriosis with Elagolix.
Leyland N; Estes SJ; Lessey BA; Advincula AP; Taylor HS
J Womens Health (Larchmt); 2021 Apr; 30(4):569-578. PubMed ID: 32975461
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.
Surrey E; Taylor HS; Giudice L; Lessey BA; Abrao MS; Archer DF; Diamond MP; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Singh SS; Rechberger T; Agarwal SK; Duan WR; Schwefel B; Thomas JW; Peloso PM; Ng J; Soliman AM; Chwalisz K
Obstet Gynecol; 2018 Jul; 132(1):147-160. PubMed ID: 29889764
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of elagolix in the treatment of endometriosis.
Perricos A; Wenzl R
Expert Opin Pharmacother; 2017 Sep; 18(13):1391-1397. PubMed ID: 28737050
[TBL] [Abstract][Full Text] [Related]
15. Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women.
Archer DF; Ng J; Chwalisz K; Chiu YL; Feinberg EC; Miller CE; Feldman RA; Klein CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31650182
[TBL] [Abstract][Full Text] [Related]
16. Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov Model.
Winzenborg I; Polepally AR; Nader A; Mostafa NM; Noertersheuser P; Ng J
CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):466-475. PubMed ID: 32621325
[TBL] [Abstract][Full Text] [Related]
17. Elagolix as a Novel Treatment for Endometriosis-Related Pain.
Fantasia HC
Nurs Womens Health; 2019 Aug; 23(4):366-369. PubMed ID: 31276630
[TBL] [Abstract][Full Text] [Related]
18. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.
Taylor HS; Dun EC; Chwalisz K
Pain Manag; 2019 Sep; 9(5):497-515. PubMed ID: 31434540
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Chiney MS; Ng J; Gibbs JP; Shebley M
Clin Pharmacokinet; 2020 May; 59(5):617-627. PubMed ID: 31713224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]